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ABSTRACT 
Purpose: Anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies 
(mABs) are effective in the treatment of metastatic colorectal cancer (mCRC) patients.  
RAS status and tumour location (sidedness) are predictive markers of patients’ response 
to anti-EGFR mABs.  Recently, low microRNA-31-3p expression levels have been 
correlated with clinical benefit from the anti-EGFR mAb cetuximab.  Here we aimed to 
validate the predictive power of microRNA-31-3p in a prospective cohort of chemo-
refractory mCRC patients treated with single agent anti-EGFR mABs.  
Experimental Design:  microRNA-31-3p was tested by in-situ hybridization in ninety-
one pre-treatment core biopsies from metastatic deposits of forty-five mCRC patients.  
Sequential tissue biopsies obtained before treatment, at the time of partial response, 
and at disease progression were tested to monitor changes in microRNA-31-3p 
expression over treatment.   MicroRNA-31-3p expression, sidedness, and RAS status in 
pre-treatment cell-free DNA were combined in multivariable regression models to assess 
the predictive value of each variable alone or in combination.     
Results: Patients with low microRNA-31-3p expression in pre-treatment biopsies 
showed better overall response rate, as well as better progression free and overall 
survival, compared to those with high microRNA-31-3p expression.  The prognostic 
effect of microRNA-31-3p was independent from age, gender and sidedness.  No 
significant changes in the expression of microRNA-31-3p were observed when 
sequential tissue biopsies were tested in long-term or poor responders to anti-EGFR 
mABs.  MicroRNA-31-3p scores were similar when pre-treatment biopsies were 
compared with treatment-naïve archival tissues (often primary CRC).   
Conclusions: Our study validates the role of microRNA-31-3p as potential predictive 
biomarker of selection for anti-EGFR mABs.   
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STATEMENT OF TRANSLATIONAL RELEVANCE 
RAS status and sidedness represent negative predictive markers of response to anti-
EGFR treatment in metastatic colorectal cancer (mCRC) patients.   Recently, microRNA-
31-3p has emerged as a potential biomarker for the selection of candidates to first line 
treatment with a combination of chemotherapy and anti-EGFR treatment.   Here we 
confirm the predictive value of microRNA-31-3p in a prospective cohort of chemo-
refractory mCRC patients treated with single agent cetuximab in a phase II trial.   We 
show that: microRNA-31-3p can be scored using in situ hybridization on pre-treatment 
biopsies; microRNA-31-3p expression is comparable between primary CRC and 
metastases; microRNA-31-3p expression does not change during cetuximab treatment; 
and that patients with low microRNA-31-3p expression had better disease control, 
progression free survival, and overall survival compared to patients with high microRNA-
31-3p expression.  We suggest that microRNA-31-3p analysis might be incorporated in 
the work-up of mCRC along with tumour sidedness and RAS testing, in order to further 
refine the selection of potential responders to anti-EGFR treatments. 
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INTRODUCTION 
Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide (1,2). 
Epidermal Growth Factor Receptor (EGFR) monoclonal antibodies (mABs) are effective 
in metastatic CRC (mCRC) and can be used alone or in combination with chemotherapy 
(3).  Mutations in the RAS pathway are negative predictive biomarkers of response to 
anti-EGFR antibodies in patients with mCRC, thus RAS testing on tissue is routinely 
performed in clinical practice for patient selection (3). 
We and others have recently shown that implementing RAS genotyping in pre-treatment 
circulating cell-free (cf) DNA can identify patients who are unlikely to benefit from anti-
EGFR therapies (4,5).  Furthermore, our mathematical modelling indicated that resistance 
to anti-EGFR antibodies is often polyclonal, suggesting that multiple genetic and non-
genetic drivers might contribute to treatment failure (5).          
MicroRNAs (miRs) are short non-coding RNAs controlling gene expression at post-
transcriptional level (6).  MiRs are involved in developmental and physiological 
processes (6), and are often dysregulated in pathological conditions such as cancer and 
inflammation (7).  MiR dysregulation is frequently observed in CRC and multiple lines of 
evidence suggest that miRs affect a number of cancer hallmarks (8), and drive CRC 
initiation (9), progression (10) and resistance to treatment (11).  Given their relative 
stability in tissues and other bio-fluids (12,13), miRs have been proposed as potential 
biomarkers for CRC early detection (14,15), diagnosis (16) and prognosis (17).  
MiR up-regulation and/or single nucleotide polymorphisms in miR target genes have 
been postulated as potential determinants of resistance and sensitivity to anti-EGFR 
mABs in early and metastatic CRC (18-21).  MicroRNA-31-3p (miR-31-3p) expression 
levels have been examined by RT-PCR in retrospective analyses of the FIRE-3, 
PICCOLO, NEW-EPOC and PETACC8 trials (22-26); in these studies low miR-31-3p 
expression was associated with improved outcome and prolonged benefit from anti-
EGFR treatment.  Real-Time PCR based assays for the analysis of miR-31-3p on 
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formalin-fixed paraffin embedded (FFPE) tissues are at an advanced stage of validation 
(23,27).  
The PROSPECT-C trial was a phase II trial of single agent anti-EGFR antibodies in 
chemo-refractory mCRC.  Patients underwent repeated tissue biopsies of metastatic 
deposits before and after treatment as well as at the time of treatment response in case 
of partial response (5).   
In this study we aimed to: (a) validate the association between miR-31-3p expression 
and clinical benefit from anti-EGFR treatment in pre-treatment tissue biopsies; (b) test 
changes in miR-31-3p expression in serial tissue biopsies during treatment in order to 
assess whether miR-31-3p might be a potential biomarker of acquired resistance; (c) 
test whether combining miR-31-3p with RAS testing in cfDNA might improve patient 
selection. 
 
METHODS 
Trial design and patient characteristics 
The Prospect-C trial (ClinicalTrials.gov identifier: NCT02994888), was a prospective, 
phase II, open-label, single centre, non-randomised study of biomarkers of response 
and resistance to anti-EGFR therapies in KRAS/NRAS wild-type (wt) chemo-refractory 
mCRC.  Patients who were at least 18 years old and had a World Health Organisation 
performance status (PS) of 0-2 were considered eligible for this study if they fulfilled all 
the following criteria: I) chemo-refractory (at least two lines of chemotherapy) metastatic 
disease; II) KRAS/NRAS wt (on archival material according to clinically accredited 
molecular testing); III) measurable disease; and IV) metastatic sites amenable to biopsy. 
Patients received cetuximab/panitumumab through the Cancer Drug Fund.  Written 
informed consent was obtained from all patients.  The study was carried out in 
accordance with the Declaration of Helsinki and was approved by National Institutional 
review boards [National Research Ethics Service (NRES): 12/LO/0914].  The objectives 
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of the study were to validate known mechanisms and identify novel drivers of 
response/resistance to cetuximab.  Treatment consisted of cetuximab 500mg/m2 once 
every 2 weeks until progression or intolerable side effects.  All but one patient received 
cetuximab and were anti-EGFR naïve at the time of trial entry; the aforementioned 
patient was switched to panitumumab due to a Common Toxicity Criteria for Adverse 
Events (CTCAE) 3.0 Grade II allergic reaction after the first dose of cetuximab, and had 
previously received 3 cycles of fluorouracil, oxaliplatin and cetuximab combination with 
partial response (PR) as neo-adjuvant chemotherapy for liver resection in the context of 
the NewEPOC trial 13 months before entering the PROSPECT-C trial. 
All participants were required to have mandatory pre-treatment biopsies [baseline (BL), 
6 cores], biopsies at 3 months [if PR by Response Evaluation Criteria In Solid Tumors 
(RECIST) v1.1 criteria (6 cores)] where clinically and technically feasible, and post-
treatment at the time of progressive disease (PD) (6 cores from two suitable progressing 
metastatic sites).  Archival material (primary cancer or original diagnostic biopsies) was 
assessed where available.  Plasma for circulating cell free DNA (cfDNA) analysis was 
collected every 4 weeks until disease progression. 
 
Analysis of miRNA 31-3p expression using In-situ hybridisation 
In-situ hybridisation (ISH) assays for miR-31-3p expression in baseline tissue was performed 
using miRCURY® LNA® miRNA ISH Optimization Kit for FFPE (Qiagen, Hilden, Germany).  
Archival tumour material at diagnosis was tested if available (n=12).  ISH on tissue sections 
was performed following the Exiqon protocol with some modifications.  Initially paraffin was 
removed with Xylene incubation for five minutes followed by ethanol 100% incubation for 
another five minutes.  Tissue sections were then dehydrated in ThermoBrite hybridizer 
(Leica Biosystems, Wetzlar, Germany) containing 20 ug/mL of Proteinase K (Roche, Basel, 
Swrizerland) for 15 minutes at 37 oC.  The dehydration reaction was stopped by immersing 
the slides in PBS, and a pre-hybridization step was then performed by adding 1X ISH buffer 
Research. 
on June 18, 2019. © 2019 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on April 5, 2019; DOI: 10.1158/1078-0432.CCR-18-3769 
8 
 
(Exiqon, Vedbaek, Denmark) and incubating the sections for 15 minutes at 56 °C.  Following 
the removal of the pre-hybridization solution, previously denatured (90 °C) miRCURY® LNA 
microRNA detection probe (hsa-miR-31-3p, cat n. YD006116560, Exiqon, Vedbaek, 
Denmark) was added to the sections at a 200nM concentration; sections were incubated 
with the detection probe overnight at 56 °C.  The following day tissue sections were 
sequentially immersed in 5X, 1X, and 0.2X SCC solutions at hybridization temperature for 
five minutes each, and finally transferred in PBS solution at room temperature.  Blocking was 
performed at 30 °C in hybridizer followed by incubation with anti-Digoxygenin-AP fragments 
(Sigma-Aldrich, St. Louis, MO,) for 1h.  The sections were then washed three times with 
PBS-Tween 0.2% for five minutes each and incubated for 2h with BCIP®/NBT Liquid 
Substrate System (Sigma-Aldrich) for developing the reaction.  The reaction was stopped 
with by immersing the slides in KTBT buffer and counterstained in Nuclear Fast Red (Vector 
Laboratories, Burlingame, CA, USA).  The sections were then dehydrated by ethanol 100% 
and Xylene incubations (for 5 minutes each) and covered with a coverslip. 
MiR-31-3p expression was graded by two independent pathologists as follows:  0 = no 
staining; 1+ = weak staining; 2+ = intermediate staining; and 3+ = strong staining.  
Patients with a 0 or 1+ expression score were deemed as low expressors whereas those 
with a score of 2+ or 3+ were deemed as high expressors. 
 
Analysis of miRNA 31-3p expression using Real-Time PCR 
Prior to RNA extraction, samples were reviewed by the pathologist and cancer areas 
were marked for subsequent macro-dissection.  Total RNA from FFPE slides (4 x 4um 
sections) was extracted using the Ambion Recover All Isolation Kit (Thermo Fisher 
Scientific, Waltham, MA, USA), according to manufacturer’s instructions. RNA quantity 
and quality were assessed by NanoDrop2000 (Thermo Fisher Scientific, Waltham, MA, 
USA).  Ten nanogram of total RNA were retrotranscribed using the TaqMan® MicroRNA 
Reverse Transcription kit (Thermo Fisher Scientific, Waltham, MA, USA), and RT-PCR 
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was performed using the TaqMan® assay for miR-31-3p (assay ID 002113).  RNU48 
was used as housekeeping gene for normalization, and relative expression was 
calculated using the 2ΔCt  method.  MiR-31-3p expression was scored as high or low 
based on the median of the distribution. 
 
Statistical Analysis 
Progression free survival (PFS) was calculated from start of treatment with cetuximab to 
date of progression assessed radiologically, or clinically.  Overall survival (OS) was 
calculated from start of cetuximab to date of death from any cause or last day of follow-
up.  Differences in PFS and OS between patients with low expression and high miR-31-
3p expression pre-treatment were calculated using the Kaplan-Meier method and 
compared using the log-rank test.  Chi-square test was used to assess the effect of miR 
expression on overall response to cetuximab treatment.  Univariate and multivariate 
analysis using Cox proportional hazards method were performed to assess effects of 
age, gender, sidedness of tumour in all 42 patients.  In the 34 patients for whom 
baseline ctDNA results were available, a similar approach was used and multivariate 
analysis performed.  A p value of <0.05 was considered significant.   
All the authors reviewed and approved the final manuscript. Researcher performing 
experiments and scoring tissues were blind to clinical outcome information. Analysis was 
performed by trial statisticians. 
 
RESULTS 
The PROSPECT-C trial recruited forty-five eligible patients between November 2012 
and December 2016 (Figure 1).  Forty-five percent of patients achieved disease control 
[partial response (PR) or stable disease by RECIST 1.1. criteria]; median PFS and OS 
were 2.6 months (95% confidential interval (CI): 1.9 – 4.2) and 8.2 months (95% CI: 4.2 - 
12.0), respectively.  These data have been previously reported by our group (5) and are 
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in keeping with available literature for single agent anti-EGFR treatments in chemo-
refractory mCRC (28). 
In order to test the association between miR-31-3p expression and benefit from anti-
EGFR treatment we initially scored miR-31-3p by ISH in ninety-one baseline tissue core 
biopsies from forty-five patients.  Forty-two of those patients (88 cores) could be tested 
further in this study, as, following extensive previous analyses (5,29), no cancer was left 
in 3 cases.   
MiR-31-3p was marked as low if scored negative or 1+, and as high if scored 2+ or 3+ in 
cancer (Figure 2), while stromal miR-31-3p staining due to inflammatory or immune 
infiltrate (Supplementary Figure 1) was not taken into account. Positive cells in the 
stroma were represented by plasma cells, macrophages and endothelial cells, and most 
of them showed a faint miR-31-3p expression, with only a limited number of cells 
characterized by a moderate expression.  No significant difference in the proportion of 
positive stromal cells was observed between anti-EGFR responder and resistant 
tumours.   
At least 2 different slides for each core were tested and concordance in miR-31-3p 
scoring among different sections from the same core was 100%.  In thirty-two patients, 
two different cores from the same metastasis were tested, although, in four cases one of 
the two cores showed only necrosis and/or inflammation and thus comparison with its 
parental core was not possible.  The concordance in miR-31-3p scoring among different 
cores in the remaining twenty-eight patients was 89% (3 cases scored in different 
categories and were attributed to the high miR-31-3p category as the average score was 
above 1+).  Overall, twenty-four patients were scored as miR-31-3p low and eighteen as 
miR-31-3p high; patients’ demographics based on miR-31-3p expression are presented 
in Table 1.   
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In order to validate the results obtained by ISH, we performed miR-31-3p expression 
analysis using RT-PCR on 46 cores from 18 patients for whom material was available 
for RNA extraction.  Two different core biopsies were available in 19 cases and the 
average expression (based on RT-PCR) between the two cores was used to determine 
the miR-31-3p scoring; for the remaining 8 cases only one core biopsy was tested.  The 
46 cores included 4 primary tumours, 29 pre-treatment (baseline), 4 on-treatment (at the 
time of partial response) and 9 post-treatment (progression) biopsies.  A statistically 
significant correlation (chi-squared exact test p: 0.003) with 77% concordance between 
the two miR-31-3p expression tests was observed (Supplementary Table 1). 
Next we tested the association between miR-31-3p score based on ISH and clinical 
benefit from anti-EGFR mABs.  Low miR-31-3p expression was associated with better 
overall response rate (ORR) defined as partial response or stable disease, with 58.3% 
(14/24) patients showing response in the miR-31-3p low group versus 22.2% (4/18) in 
the miR-31-3p high group (Supplementary Table S2; chi-squared exact test p: 0.029).  
A significant depth and duration of response was observed in patients with low miR-31-
3p expression (Figure 3A and 3B).  Median PFS was 4.21 months (CI: 1.91-5.56) and 
2.27 months (CI: 1.55-2.53) in patients with low and high miR-31-3p respectively [HR for 
miR-31-3p high: 2.03 (CI: 1.06-3.91); p: 0.03] (Figure 3C).  Similarly, median OS was 
8.88 months (CI: 5.53-18.36) and 4.14 months (CI: 2.96-8.68) in patients with low and 
high miR-31-3p respectively [HR for miR-31-3p high: 2.20 (CI: 1.09-4.43); p: 0.03] 
(Figure 3D).  Multivariable Cox regression analysis including miR-31-3p expression, age 
at diagnosis, gender, and sidedness (30) in the trial cohort (n=42) confirmed that miR-
31-3p was an independent predictor of PFS (Supplementary Table S3) and OS 
(Supplementary Table S4).  
Changes in miR-31-3p expression during single-agent cetuximab treatment have never 
been investigated before.  Here we took advantage of repeated serial tissue sampling in 
our trial and we tested whether miR-31-3p scoring is altered during or after EGFR 
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inhibition. Analysis of nine patients with long-term response (PFS≥6 months) and 
patients with primary progression (PFS≤3 months) revealed no changes in miR-31-3p 
scoring in either of the two groups (Supplementary Table S5 and Figure 4A).  Indeed, 
analysis of liver, nodal, abdominal wall and pelvic metastases showed consistent miR-
31-3p expression even when different metastases were tested (Figure 4A and 4B). 
Comparison of miR-31-3p score between archival, treatment naïve tissue (primary CRC 
in most of the cases) and pre-cetuximab tissue biopsies (Supplementary Table S6) 
was concordant in 11/12 cases (Fisher exact test p: 0.01) (Supplementary Table S7). 
We and others have recently demonstrated the predictive value of RAS testing in pre-
treatment cfDNA as a valuable and more specific alternative to tissue analysis in the 
selection of patients eligible for anti-EGFR treatments.(4,5)  When we included miR-31-
3p in a multivariable Cox regression analysis including age at diagnosis, gender, 
sidedness and RAS genotyping in pre-treatment cfDNA in patients for whom all the 
information were available (n=34), miR-31-3p showed no independent value in 
predicting PFS (Supplementary Table S8) or OS (Supplementary Table S9).  In 
keeping with these data, when we generated a statistical model combining miR-31-3p 
status in tissues and RAS genotyping in pre-treatment cfDNA (presence/absence of 
mutations) (Supplementary Figure 2A-C and Supplementary Tables S10 and S11), 
the interaction tests for ORR, PFS and OS were non-significant (p: 0.213; p: 0.178 and 
p: 0.067 respectively).   Among patients who tested as RAS wt in cfDNA from baseline 
bloods, ORR was 78%, median PFS was 5.10 months (CI: 1.91-16.88) and median OS 
was 15.23 months (CI: 1.91-34.08) in patients with low miR-31-3p expression (n=9).  On 
the contrary, ORR was 25%, median PFS was 2.27 months (CI: 1.91-16.88) and median 
OS was 4.67 months (CI: 1.51-12.04) in patients with high miR-31-3p expression (n=8). 
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DISCUSSION 
MiR-31-3p expression has been tested in a number of retrospective series and 
retrospective analyses of prospective trials (18,22-24,31).  Low miR-31-3p expression 
has been associated with sustained PFS and OS as well as improved ORR in response 
to EGFR inhibitors.  Although these findings have been validated in several studies, the 
interpretation of these data remains challenging due to the fact that in most of these 
series anti-EGFR mAbs (cetuximab or panitumumab) were used in combination with 
different chemotherapy backbones and in different lines of treatment.  In the 
PROSPECT-C trial (5), cetuximab was used as a single agent in a prospective and 
homogeneous cohort of chemo-refractory mCRC patients; furthermore miR-31-3p was 
tested in ad hoc pre- and post-treatment tissues biopsies.  Thus, despite a relatively 
small sample size, the trial provided an excellent opportunity to validate the predictive 
role of miR-31-3p in a prospective cohort and allowed to test dynamic changes in miR-
31-3p expression over-treatment.  The results presented here are largely consistent with 
available literature (22-24,27) and suggest that low miR-31-3p might be an indicator of 
response and better prognosis in patients treated with anti-EGFR mAbs. 
Even though our data align well with available literature, several questions remain open.  
Firstly, the biology underpinning a potential role for miR-31-3p in driving resistance to 
anti-EGFR agents is not clear.  Pre-clinical in vitro and in vivo data in colon and lung 
cancer respectively suggest that miR-31-3p targets a number of negative regulators of 
the RAS-MAPK cascade (32,33).  However, despite the link between miR-31-3p over-
expression and RAS signalling pathway activation appears solid, no experimental 
evidence has, as yet,  confirmed whether these mechanisms are responsible for 
resistance to cetuximab. 
A second question relates to the source of material and the technology to be used for 
miR-31-3p testing.  MiR-31-3p is over-expressed in early stages of sporadic and 
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inflammation-related CRC carcinogenesis but expression does not appear to change in 
more advanced or metastatic stages of disease (34-36).  In keeping with these data, no 
significant changes in miR-31-3p scoring were observed in our trial when comparing 
primary cancers and metastatic sites.  Similarly, in our series, no changes in miR-31-3p 
scoring were observed in sequential tissues biopsies collected before, during, and after 
cetuximab treatment.  On the contrary, in the NEW-EPOC trial (22), a non-significant 
correlation for miR-31-3p expression was observed between paired primary CRC 
specimens and liver metastases in patients receiving pre-operative cetuximab, while a 
positive and significant correlation was observed in patients treated with chemotherapy 
alone, suggesting that cetuximab treatment might induce changes in miR-31-3p 
expression.  One of the potential explanations for the discrepancy between the NEW-
EPOC (22) and the PROSPECT-C trial (5)  is that, in the former trial, miR-31-3p levels 
were tested by ISH while in the in the latter, the analysis was performed by RT-PCR.  
Cetuximab is known to trigger intra-tumour inflammatory infiltration in liver metastases, 
with an enrichment of CD3-, CD8-, and CD56-positive cells (37).  Given MiR-31-3p is 
also involved in immune and inflammatory cells homeostasis (38-41), its over-
expression might sometimes be due to intra-tumour infiltration from lymphocites or 
inflammatory cells.  Under these circumastances, despite tissue micro-dissection, 
contamination by inflammatory cells might potentially lead to a bias in miR-31-3p scoring 
when using high sensitivity RT-PCR-based assays.  In line with this hypothesis, our ISH 
did detect areas of miR-31-3p over-expression in the stromal compartment of tumours 
otherwise scored as miR-31-3p low.  Furthermore, even though the comparison between 
ISH-based and RT-PCR-based miR-31-3p scoring in our cohort showed a good 
concordance, several cases were classified in different miR-31-3p expression categories 
by the two assays, thus highlighting some hurdles in selecting the best approach for 
evaluating miR-31-3p expression as a biomarker for anti-EGFR mABs.  Given RT-PCR 
based assays have been recently validated for miR-31-3p clinical testing (23,27), 
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caution in the analysis and interpretation of data should be exerted in cases with intense 
inflammatory and immune infiltrate as these might affect miR-31-3p classification. 
Selection of mCRC patients’ candidate to anti-EGFR treatment relies on primary tumour 
location (sidedness) (30) and RAS testing (3).  As we and others have suggested (4,5), 
moving RAS testing to plasma cfDNA might represent a more sensitive and 
cost/effective option than tissue analysis.  In our study we combined RAS genotyping in 
cfDNA with miR-31-3p expression in order to test whether this would result in a more 
accurate prediction of response to cetuximab.  The test for interaction between the two 
categorical variables was not significant possibly due to the very small sample size, 
however, in patients with no cfDNA RAS abnormalities, ORR, PFS and OS appeared 
better for patients with miR-31-3p low tumours.  While larger studies will need to confirm 
these findings, a key question remains open: do we need another test to select mCRC 
patients for cetuximab treatment, or are we at risk of ultra-selecting patients?  Our data, 
in line with the analyses of FIRE-3 (26) trial, suggest that miR-31-3p expression may be 
an indicator of depth of response to anti-EGFR inhibition; this, in our opinion, might 
represent the ideal scenario where a more accurate identification of patients likely to 
achieve resectability and/or symptom control may justify a more thorough selection of 
patients (Figure 5).    
In conclusion, our results confirm the potential predictive role of miR-31-3p for the 
selection of patients undergoing anti-EGFR treatment.  Further studies are needed to 
test if miR-31-3p might be combined with RAS testing in cfDNA to further identify best 
responders in specific clinical niches.  
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FIGURE LEGENDS 
Figure 1. Schematic overview of the PROSPECT-C trial. Chemo-refractory, 
metastatic colorectal cancer (mCRC) patients meeting all the inclusion criteria 
underwent serial tissue biopsies from metastatic deposits prior to anti-EGFR treatment, 
after 3 months of treatment in case of partial response (PR), and at time of progression 
(PD).  EGFR=epidermal growth factor receptor. 
 
Figure 2. miR-31-3p in-situ hybridization in pre-treatment biopsies. Examples of 
miR-31-3p expression tested by in situ hybridization in tissue biopsies obtained from 
metastatic deposits prior to anti-EGFR treatment in the PROSPECT-C trial.  The left 
panels show examples of cases scored as miR-31-3p “Low” based on a score of 0 (top) 
or 1+ (bottom).  The right panels show examples of cases scored as miR-31-3p “High” 
based on a score of 2+ (top) or 3+ (bottom). Original magnifications = 20x. In each case, 
a higher magnification of miR-31-3p expression in representative neoplastic cells is 
shown as right bottom inlet.  EGFR=epidermal growth factor receptor. 
 
Figure 3. miR-31-3p and clinical benefit from anti-EGFR therapy in the PROSPECT-
C trial.  Waterfall (A) and spider (B) plots show depth (based on RECIST 1.1 criteria) 
and duration of response based on miR-31-3p expression.  Kaplan-Meier curves for 
progression free (C) and overall (D) survival according to miR-31-3p expression.  
EGFR=epidermal growth factor receptor. 
 
Figure 4. Analysis of miR-31-3p expression in sequential tissue biopsies in the 
PROSPECT-C trial.  (A) MiR-31-3p expression was tested by in-situ hybridization in 
pre- and post-treatment tissue biopsies as well as after 3 months of treatment in case of 
partial response.  MiR-31-3p scoring did not change over treatment in liver (1024 and 
1041) or in nodal (1026) cancer deposits.  (B) Axial enhanced CT images performed at 
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baseline and, 20 months later at end of treatment due to RECIST 1.1 progression in 
non-target disease in patient 1005.  The images show maintained benefit in the target 
pelvic lesion (yellow arrow) and a mixed response in the non-target abdominal wall 
disease with stable appearances of the right para-median lesion (white asterisk) and 
progression of the left para-median lesion (arrowhead).  At baseline the biopsy was 
obtained from the target pelvic lesion (yellow arrow), at progression the biopsy was of 
the left para-median lesion (the biopsy tract can be seen in the subcutaneous tissue – 
white oval). No changes in miR-31-3p staining were observed in sequential biopsies 
from the different regions. Original magnifications = 20x. 
 
Figure 5. Proposed workflow for the analysis of miR-31-3p expression in 
metastatic CRC patients. miR-31-3p might be recommended for left-sided, RAS wild-
type patients eligible for resection and/or metastasectomy or for disease/symptoms 
control. 
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TABLE 
 
Table 1. Demographics of the PROSPECT-C Trial based on miR-31-3p expression (n=42) 
 
 miR-31-3p low miR-31-3p high 
Age at registration: Median (IQR) 69.6 (62.5-75.9) 67.9 (59.3-73.3) 
   
Gender   
Females   8 (33.3%)   8 (44.4%) 
Males 16 (66.7%) 10 (55.6%) 
   
RAS pathway aberration in pre-treatment cfDNA   
Absent 9 (50%) 8 (50%) 
Present 9 (50%) 8 (50%) 
   
Side   
Left 19 (79.2%) 12 (66.7%) 
Right   5 (20.8%)   6 (33.3%) 
   
Previous treatment lines: Median (IQR) 1 (1-2) 2 (1-2) 
   
IQR= interquartile range; cfDNA= circulating cell-free DNA 
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